<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911062</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-011-221</org_study_id>
    <nct_id>NCT04911062</nct_id>
  </id_info>
  <brief_title>HTX-011 in Spinal Surgery</brief_title>
  <official_title>A Phase 2, Two-Part, Multicenter Study of HTX-011 in Spinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter study in subjects undergoing an open 2-level, lumbar&#xD;
      laminectomy without fusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>From the time the subject signs the ICF through the Day 29 Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline through 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of maximum concentration (Tmax)</measure>
    <time_frame>Baseline through 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from Time 0 to the time of last quantitative concentration (AUClast)</measure>
    <time_frame>Baseline through 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Baseline through 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (tÂ½)</measure>
    <time_frame>Baseline through 120 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Post-Operative Pain</condition>
  <condition>Lumbar Laminectomy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Bupivacaine HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine HCl without epinephrine, via injection into the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 (bupivacaine/meloxicam) via application into the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (optional): HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-011 (bupivacaine/meloxicam) via application into the surgical site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCI without epinephrine</intervention_name>
    <description>75 mg administered via injection into the surgical site.</description>
    <arm_group_label>Cohort 1: Bupivacaine HCl</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.</description>
    <arm_group_label>Cohort 2: HTX-011</arm_group_label>
    <other_name>Cohort 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>HTX-011 (bupivacaine/meloxicam) dose up to 400 mg/12 mg administered via application into the surgical site.</description>
    <arm_group_label>Cohort 3 (optional): HTX-011</arm_group_label>
    <other_name>Cohort 3 (optional)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luer Lock Applicator</intervention_name>
    <description>Applicator for instillation.</description>
    <arm_group_label>Cohort 2: HTX-011</arm_group_label>
    <arm_group_label>Cohort 3 (optional): HTX-011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is scheduled to undergo an open 2-level lumbar laminectomy without fusion under&#xD;
             general anesthesia..&#xD;
&#xD;
          -  Has not previously undergone multilevel laminectomy or fusion.&#xD;
&#xD;
          -  Can ambulate at least 20 meters with optional use of an assisted device for balance.&#xD;
&#xD;
          -  Females are eligible only if not pregnant, not lactating, not planning to become&#xD;
             pregnant during the study, sterile; or is at least 2 years post-menopausal; or is in a&#xD;
             monogamous relationship with a partner who is surgically sterile; or using acceptable&#xD;
             contraceptives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a planned concurrent surgical procedure.&#xD;
&#xD;
          -  Has a contraindication or a known or suspected history of hypersensitivity to required&#xD;
             study medications.&#xD;
&#xD;
          -  Has a pre-existing concurrent painful physical/restrictive condition expected to&#xD;
             require analgesic treatment in the postoperative period.&#xD;
&#xD;
          -  Has a history of an intrathecal drug pump or spinal cord stimulator.&#xD;
&#xD;
          -  Has a known or suspected daily use of opioids for a period of at least 30 days in the&#xD;
             previous 6 months.&#xD;
&#xD;
          -  Has taken meloxicam or any other NSAID within 10 days prior to the scheduled surgery.&#xD;
&#xD;
          -  Has been administered bupivacaine within 5 days or any local anesthetic within 72&#xD;
             hours prior to the scheduled surgery.&#xD;
&#xD;
          -  Has taken selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine&#xD;
             reuptake inhibitors (SNRIs), gabapentin, pregabalin to control pain within 1 month&#xD;
             prior to the scheduled surgery.&#xD;
&#xD;
          -  Has been administered systemic steroids within 10 days prior to the scheduled surgery.&#xD;
&#xD;
          -  Received an investigational product or device in a clinical trial within 30 days or&#xD;
             within 5 elimination half-lives.&#xD;
&#xD;
          -  Has a known or suspected history of drug abuse or alcohol abuse (within 10 years).&#xD;
&#xD;
          -  Has a history of clinically significant cardiac abnormality, coronary artery bypass&#xD;
             graft surgery within 12 months, or suspected coagulopathy or uncontrolled&#xD;
             anticoagulation.&#xD;
&#xD;
          -  Has loss of sensation in lower extremities or peripheral neuropathy that interferes&#xD;
             with balance or walking.&#xD;
&#xD;
          -  Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.&#xD;
&#xD;
          -  Has uncontrolled anxiety, psychiatric, or neurological disorder.&#xD;
&#xD;
          -  Had a malignancy in the last year, with the exception of nonmetastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Has undergone 3 or more surgeries within 12 months.&#xD;
&#xD;
          -  Has a known history of glucose-6-phosphate dehydrogenase deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Visonneau, MD, MSc</last_name>
    <phone>858-251-7232</phone>
    <email>svisonneau@herontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>local anesthetic</keyword>
  <keyword>lumbar laminectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

